Oaktree Acquisition III Life Sciences (OACC) vs Vendome Acquisition I (VNME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vendome Acquisition I (VNME) has outperformed Oaktree Acquisition III Life Sciences (OACC) over the past year, gaining 3.5% versus a gain of 1.9%. Oaktree Acquisition III Life Sciences is the larger company by market cap ($264.3 million vs $257.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OACC | VNME |
|---|---|---|
| Share price | $10.75 | $10.31 |
| Market cap | $264.26M | $257.75M |
| 1-day change | -0.09% | 0.00% |
| YTD return | +1.70% | +2.79% |
| 1-year return | +1.91% | +3.51% |
| P/E ratio (TTM) | 38.39 | — |
| EPS (TTM) | $0.28 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.88 | $10.33 |
| 52-week low | $10.50 | $9.94 |
| Distance from 52-week high | -1.15% | -0.19% |
| Average volume | 31.29K | 25.76K |
| Shares outstanding | 19.78M | 20.00M |
| Sector | Finance | Finance |
| Industry | Blank Checks | Blank Checks |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Oaktree Acquisition III Life Sciences
OACC stock →Oaktree Acquisition Corp. III Life Sciences does not have significant operations.
Finance · Blank Checks
About Vendome Acquisition I
VNME stock →Vendome Acquisition Corporation I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Finance · Blank Checks
OACC vs VNME FAQ
Which is bigger, Oaktree Acquisition III Life Sciences or Vendome Acquisition I?
Oaktree Acquisition III Life Sciences (OACC) is larger, with a market capitalization of $264.26M compared with $257.75M for Vendome Acquisition I (VNME).
Which stock has performed better over the past year, OACC or VNME?
VNME returned +3.51% over the past 12 months, compared with +1.91% for OACC (price return, excluding dividends). Past performance does not predict future results.
Are Oaktree Acquisition III Life Sciences and Vendome Acquisition I in the same industry?
Yes. Both are classified in the Blank Checks industry within the Finance sector.